aluates Reports

$ 0.0

Automative

Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Research Report 2025

Published Date: 2025-06-03

Report Code: QYRE-Auto-36P16294

Global Hepatitis C Treatment Direct Acting Antiviral DAA Market Research Report 2024

BUY CHAPTERS

Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Research Report 2025

Code: QYRE-Auto-36P16294

Report

2025-06-03

Pages:81

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market

The global market for Hepatitis C Treatment Direct-Acting Antiviral (DAA) was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

North American market for Hepatitis C Treatment Direct-Acting Antiviral (DAA) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Hepatitis C Treatment Direct-Acting Antiviral (DAA) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Hepatitis C Treatment Direct-Acting Antiviral (DAA) include Gilead, Bristol Myers Squibb, AbbVie, Johnson & Johnson, Boehringer Ingelheim, Merck, Kawin Technology, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Hepatitis C Treatment Direct-Acting Antiviral (DAA), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatitis C Treatment Direct-Acting Antiviral (DAA).

The Hepatitis C Treatment Direct-Acting Antiviral (DAA) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hepatitis C Treatment Direct-Acting Antiviral (DAA) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Hepatitis C Treatment Direct-Acting Antiviral (DAA) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Report

Report Metric	Details
Report Name	Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market
Segment by Type	Pangenotypic Genotype-Specific or Polygenotypic
Segment by Application	Hospital Clinic Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Gilead, Bristol Myers Squibb, AbbVie, Johnson & Johnson, Boehringer Ingelheim, Merck, Kawin Technology
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Hepatitis C Treatment Direct-Acting Antiviral (DAA) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Hepatitis C Treatment Direct-Acting Antiviral (DAA) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market report?

Ans: The main players in the Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market are Gilead, Bristol Myers Squibb, AbbVie, Johnson & Johnson, Boehringer Ingelheim, Merck, Kawin Technology

What are the Application segmentation covered in the Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market report?

Ans: The Applications covered in the Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market report?

Ans: The Types covered in the Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market report are Pangenotypic, Genotype-Specific or Polygenotypic

1 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Overview

1.1 Product Definition

1.2 Hepatitis C Treatment Direct-Acting Antiviral (DAA) by Type

1.2.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Value Comparison by Type (2024 VS 2031)

1.2.2 Pangenotypic

1.2.3 Genotype-Specific or Polygenotypic

1.3 Hepatitis C Treatment Direct-Acting Antiviral (DAA) by Application

1.3.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Value by Application (2024 VS 2031)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Size Estimates and Forecasts

1.4.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue 2020-2031

1.4.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales 2020-2031

1.4.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Competition by Manufacturers

2.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Market Share by Manufacturers (2020-2025)

2.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Hepatitis C Treatment Direct-Acting Antiviral (DAA), Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Hepatitis C Treatment Direct-Acting Antiviral (DAA), Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Hepatitis C Treatment Direct-Acting Antiviral (DAA), Product Type & Application

2.7 Global Key Manufacturers of Hepatitis C Treatment Direct-Acting Antiviral (DAA), Date of Enter into This Industry

2.8 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Competitive Situation and Trends

2.8.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Hepatitis C Treatment Direct-Acting Antiviral (DAA) Players Market Share by Revenue

2.8.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Scenario by Region

3.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Region: 2020-2031

3.2.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Region: 2020-2025

3.2.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Region: 2026-2031

3.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Region: 2020-2031

3.3.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Region: 2020-2025

3.3.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Region: 2026-2031

3.4 North America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Facts & Figures by Country

3.4.1 North America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Country (2020-2031)

3.4.3 North America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Facts & Figures by Country

3.5.1 Europe Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Country (2020-2031)

3.5.3 Europe Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Facts & Figures by Region

3.6.1 Asia Pacific Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Region (2020-2031)

3.6.3 Asia Pacific Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Facts & Figures by Country

3.7.1 Latin America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Country (2020-2031)

3.7.3 Latin America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Facts & Figures by Country

3.8.1 Middle East and Africa Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Country (2020-2031)

3.8.3 Middle East and Africa Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Type (2020-2031)

4.1.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Type (2020-2025)

4.1.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Type (2026-2031)

4.1.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Market Share by Type (2020-2031)

4.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Type (2020-2031)

4.2.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Type (2020-2025)

4.2.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Type (2026-2031)

4.2.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Market Share by Type (2020-2031)

4.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Price by Type (2020-2031)

5 Segment by Application

5.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Application (2020-2031)

5.1.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Application (2020-2025)

5.1.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Application (2026-2031)

5.1.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Market Share by Application (2020-2031)

5.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Application (2020-2031)

5.2.1 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Application (2020-2025)

5.2.2 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Application (2026-2031)

5.2.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Market Share by Application (2020-2031)

5.3 Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Gilead

6.1.1 Gilead Company Information

6.1.2 Gilead Description and Business Overview

6.1.3 Gilead Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Gilead Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product Portfolio

6.1.5 Gilead Recent Developments/Updates

6.2 Bristol Myers Squibb

6.2.1 Bristol Myers Squibb Company Information

6.2.2 Bristol Myers Squibb Description and Business Overview

6.2.3 Bristol Myers Squibb Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Bristol Myers Squibb Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product Portfolio

6.2.5 Bristol Myers Squibb Recent Developments/Updates

6.3 AbbVie

6.3.1 AbbVie Company Information

6.3.2 AbbVie Description and Business Overview

6.3.3 AbbVie Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales, Revenue and Gross Margin (2020-2025)

6.3.4 AbbVie Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product Portfolio

6.3.5 AbbVie Recent Developments/Updates

6.4 Johnson & Johnson

6.4.1 Johnson & Johnson Company Information

6.4.2 Johnson & Johnson Description and Business Overview

6.4.3 Johnson & Johnson Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Johnson & Johnson Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product Portfolio

6.4.5 Johnson & Johnson Recent Developments/Updates

6.5 Boehringer Ingelheim

6.5.1 Boehringer Ingelheim Company Information

6.5.2 Boehringer Ingelheim Description and Business Overview

6.5.3 Boehringer Ingelheim Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Boehringer Ingelheim Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product Portfolio

6.5.5 Boehringer Ingelheim Recent Developments/Updates

6.6 Merck

6.6.1 Merck Company Information

6.6.2 Merck Description and Business Overview

6.6.3 Merck Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Merck Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product Portfolio

6.6.5 Merck Recent Developments/Updates

6.7 Kawin Technology

6.7.1 Kawin Technology Company Information

6.7.2 Kawin Technology Description and Business Overview

6.7.3 Kawin Technology Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Kawin Technology Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product Portfolio

6.7.5 Kawin Technology Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Industry Chain Analysis

7.2 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Production Mode & Process Analysis

7.4 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales and Marketing

7.4.1 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Channels

7.4.2 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Distributors

7.5 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Customer Analysis

8 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Dynamics

8.1 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Industry Trends

8.2 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Drivers

8.3 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Challenges

8.4 Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Competitive Situation by Manufacturers in 2024

Table 4. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Hepatitis C Treatment Direct-Acting Antiviral (DAA) Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Hepatitis C Treatment Direct-Acting Antiviral (DAA), Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Hepatitis C Treatment Direct-Acting Antiviral (DAA), Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Hepatitis C Treatment Direct-Acting Antiviral (DAA), Product Type & Application

Table 12. Global Key Manufacturers of Hepatitis C Treatment Direct-Acting Antiviral (DAA), Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatitis C Treatment Direct-Acting Antiviral (DAA) as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Region (2020-2025) & (K Units)

Table 18. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Market Share by Region (2020-2025)

Table 19. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Region (2026-2031) & (K Units)

Table 20. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Market Share by Region (2026-2031)

Table 21. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Market Share by Region (2020-2025)

Table 23. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Market Share by Region (2026-2031)

Table 25. North America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Country (2020-2025) & (K Units)

Table 27. North America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Country (2026-2031) & (K Units)

Table 28. North America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Country (2020-2025) & (K Units)

Table 32. Europe Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Country (2026-2031) & (K Units)

Table 33. Europe Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales (K Units) by Type (2020-2025)

Table 51. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales (K Units) by Type (2026-2031)

Table 52. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Market Share by Type (2020-2025)

Table 53. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Market Share by Type (2026-2031)

Table 54. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Market Share by Type (2020-2025)

Table 57. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Market Share by Type (2026-2031)

Table 58. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Price (US$/Unit) by Type (2020-2025)

Table 59. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Price (US$/Unit) by Type (2026-2031)

Table 60. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales (K Units) by Application (2020-2025)

Table 61. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales (K Units) by Application (2026-2031)

Table 62. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Market Share by Application (2020-2025)

Table 63. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Market Share by Application (2026-2031)

Table 64. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Market Share by Application (2020-2025)

Table 67. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Market Share by Application (2026-2031)

Table 68. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Price (US$/Unit) by Application (2020-2025)

Table 69. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Price (US$/Unit) by Application (2026-2031)

Table 70. Gilead Company Information

Table 71. Gilead Description and Business Overview

Table 72. Gilead Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Gilead Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product

Table 74. Gilead Recent Developments/Updates

Table 75. Bristol Myers Squibb Company Information

Table 76. Bristol Myers Squibb Description and Business Overview

Table 77. Bristol Myers Squibb Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Bristol Myers Squibb Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product

Table 79. Bristol Myers Squibb Recent Developments/Updates

Table 80. AbbVie Company Information

Table 81. AbbVie Description and Business Overview

Table 82. AbbVie Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. AbbVie Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product

Table 84. AbbVie Recent Developments/Updates

Table 85. Johnson & Johnson Company Information

Table 86. Johnson & Johnson Description and Business Overview

Table 87. Johnson & Johnson Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. Johnson & Johnson Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product

Table 89. Johnson & Johnson Recent Developments/Updates

Table 90. Boehringer Ingelheim Company Information

Table 91. Boehringer Ingelheim Description and Business Overview

Table 92. Boehringer Ingelheim Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. Boehringer Ingelheim Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product

Table 94. Boehringer Ingelheim Recent Developments/Updates

Table 95. Merck Company Information

Table 96. Merck Description and Business Overview

Table 97. Merck Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. Merck Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product

Table 99. Merck Recent Developments/Updates

Table 100. Kawin Technology Company Information

Table 101. Kawin Technology Description and Business Overview

Table 102. Kawin Technology Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. Kawin Technology Hepatitis C Treatment Direct-Acting Antiviral (DAA) Product

Table 104. Kawin Technology Recent Developments/Updates

Table 105. Key Raw Materials Lists

Table 106. Raw Materials Key Suppliers Lists

Table 107. Hepatitis C Treatment Direct-Acting Antiviral (DAA) Distributors List

Table 108. Hepatitis C Treatment Direct-Acting Antiviral (DAA) Customers List

Table 109. Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Trends

Table 110. Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Drivers

Table 111. Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Challenges

Table 112. Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Restraints

Table 113. Research Programs/Design for This Report

Table 114. Key Data Information from Secondary Sources

Table 115. Key Data Information from Primary Sources

Table 116. Authors List of This Report

List of Figures

Figure 1. Product Picture of Hepatitis C Treatment Direct-Acting Antiviral (DAA)

Figure 2. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Share by Type: 2024 & 2031

Figure 4. Pangenotypic Product Picture

Figure 5. Genotype-Specific or Polygenotypic Product Picture

Figure 6. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Share by Application: 2024 & 2031

Figure 8. Hospital

Figure 9. Clinic

Figure 10. Others

Figure 11. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 12. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Size (2020-2031) & (US$ Million)

Figure 13. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales (2020-2031) & (K Units)

Figure 14. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Average Price (US$/Unit) & (2020-2031)

Figure 15. Hepatitis C Treatment Direct-Acting Antiviral (DAA) Report Years Considered

Figure 16. Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Share by Manufacturers in 2024

Figure 17. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Share by Manufacturers in 2024

Figure 18. Global 5 and 10 Largest Hepatitis C Treatment Direct-Acting Antiviral (DAA) Players: Market Share by Revenue in Hepatitis C Treatment Direct-Acting Antiviral (DAA) in 2024

Figure 19. Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 20. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 21. North America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Market Share by Country (2020-2031)

Figure 22. North America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Market Share by Country (2020-2031)

Figure 23. United States Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 24. Canada Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Europe Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Market Share by Country (2020-2031)

Figure 26. Europe Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Market Share by Country (2020-2031)

Figure 27. Germany Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. France Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. U.K. Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Italy Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Russia Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Asia Pacific Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Market Share by Region (2020-2031)

Figure 33. Asia Pacific Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Market Share by Region (2020-2031)

Figure 34. China Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Japan Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. South Korea Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. India Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Australia Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. China Taiwan Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Southeast Asia Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Latin America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Market Share by Country (2020-2031)

Figure 42. Latin America Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Market Share by Country (2020-2031)

Figure 43. Mexico Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Brazil Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Argentina Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Middle East and Africa Hepatitis C Treatment Direct-Acting Antiviral (DAA) Sales Market Share by Country (2020-2031)

Figure 47. Middle East and Africa Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Market Share by Country (2020-2031)

Figure 48. Turkey Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Saudi Arabia Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. UAE Hepatitis C Treatment Direct-Acting Antiviral (DAA) Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Global Sales Market Share of Hepatitis C Treatment Direct-Acting Antiviral (DAA) by Type (2020-2031)

Figure 52. Global Revenue Market Share of Hepatitis C Treatment Direct-Acting Antiviral (DAA) by Type (2020-2031)

Figure 53. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Price (US$/Unit) by Type (2020-2031)

Figure 54. Global Sales Market Share of Hepatitis C Treatment Direct-Acting Antiviral (DAA) by Application (2020-2031)

Figure 55. Global Revenue Market Share of Hepatitis C Treatment Direct-Acting Antiviral (DAA) by Application (2020-2031)

Figure 56. Global Hepatitis C Treatment Direct-Acting Antiviral (DAA) Price (US$/Unit) by Application (2020-2031)

Figure 57. Hepatitis C Treatment Direct-Acting Antiviral (DAA) Value Chain

Figure 58. Channels of Distribution (Direct Vs Distribution)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions